NeuroPace, Inc. (NPCE)

Market Cap	477.97M
Revenue (ttm)	94.86M
Net Income (ttm)	-23.99M
Shares Out	33.31M
EPS (ttm)	-0.75
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	270,264
Open	13.49
Previous Close	13.50
Day's Range	13.28 - 14.74
52-Week Range	7.56 - 18.98
Beta	1.90
Analysts	Strong Buy
Price Target	17.00 (+18.47%)
Earnings Date	Nov 4, 2025

About NPCE

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet and patient data management system; and nSight Platform, which facil...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 22, 2021
• Employees: 184
• Stock Exchange: NASDAQ
• Ticker Symbol: NPCE
• Website: https://www.neuropace.com

Financial Performance

In 2024, NeuroPace's revenue was $79.91 million, an increase of 22.14% compared to the previous year's $65.42 million. Losses were -$27.14 million, -17.64% less than in 2023.

Analyst Summary

According to 7 analysts, the average rating for NPCE stock is "Strong Buy." The 12-month stock price target is $17.0, which is an increase of 18.47% from the latest price.

Price Target

$17.0

(18.47% upside)

Analyst Consensus: Strong Buy